World Anti-Doping Code International Standard for Laboratories / World Anti-Doping Agency (WADA). - Montreal : WADA, 2011. - (International Standard for Laboratories (ISL), version 7.0, in force 1 January 2012)

The International Standard for Laboratories was first adopted in June 2003 and became effective on 1 January 2004. The enclosed represents version 7.0 that incorporates revisions to the International Standard for Laboratories that were approved by the World Anti-Doping Agency Executive Committee on 19 November 2011. The revised International Standard for Laboratories is effective as of 1 January 2012.

The World Anti-Doping Code International Standard for testing / World Anti-Doping Agency (WADA). - Montreal : WADA, 2011. - (The World Anti-Doping Code International Standard for testing (IST) Version 3.0 effective on 1 January 2012)

The International Standard for Testing was first adopted in 2003
and became effective in 2004. Further revisions to the International Standard for Testing were approved by the World Anti-Doping Agency Executive Committee on 10 May 2008.
The enclosed incorporates additional revisions to the International
Standard for Testing that were approved by the World Anti-Doping Agency Executive Committee on 17 September 2011. The revised International Standard for Testing is effective as of 1 January 2012.

Reichel C. The overlooked difference between human endogenous and recombinant erythropoietins and its implication for sports drug testing and pharmaceutical drug design. Drug Test Anal. 2011 Nov-Dec;3(11-12):883-91. doi: 10.1002/dta.388. Epub 2011 Dec 2.

Reichel C, Gmeiner G. Erythropoietin and analogs. Handb Exp Pharmacol. 2010;(195):251-94.

Reichel C, Abzieher F, Geisendorfer T. SARCOSYL-PAGE: a new method for the detection of MIRCERA- and EPO-doping in blood. Drug Test Anal. 2009 Nov;1(11-12):494-504.

Voss S, Lüdke A, Romberg S, Schänzer E, Flenker U, deMarees M, Achtzehn S, Mester J, Schänzer W. Effects of high intensity exercise on isoelectric profiles and SDS-PAGE mobility of erythropoietin. Int J Sports Med. 2010 Jun;31(6):367-71. Epub 2010 Apr 23.

False-positive detection of rhEPO remains a real concern / Beullens M, Delanghe JR, Bollen M.. - (Blood 108 (2006) 5 (1 September); p. 1779-1780)

Lasne F. No doubt about the validity of the urine test for detection of recombinant human erythropoietin. Blood. 2006 Sep 1;108(5):1778-9; author reply 1779-80.

False-positive Epo test concerns unfounded / Don Catlin, Gary Green, Michael Sekera, Paul Scott, Borislav Starcevic. - (Blood 108 (2006) 5 (1 September); p. 1778)

• PMID: 16926300
• DOI: 10.1182/blood-2006-03-006890
• Comment on:

False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise / Monique Beullens, Joris R. Delanghe, Mathieu Bollen. - (Blood 107 (2006) 12 (15 June); p. 4711-4713)

• • PMID: 16493001

  • DOI: 10.1182/blood-2006-01-0028

Abstract for: False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise

Erythropoietin (Epo) is a glycoprotein hormone that promotes the production of red blood cells. Recombinant human Epo (rhEpo) is illicitly used to improve performance in endurance sports. Doping in sports is discouraged by the screening of athletes for rhEPO in urine. The adopted test is based on a combination of isoelectric focusing and double immunoblotting, and distinguishes between endogenous and recombinant human Epo. We show here that this widely used test can occasionally lead to the false-positive detection of rhEpo (epoetin-beta) in postexercise, protein-rich urine, probably because the adopted monoclonal anti-Epo antibodies are not monospecific.

Beullens M, Delanghe JR, Bollen M. False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood 2006 107: 4711-4713.